Search results
Results from the WOW.Com Content Network
Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs. [5] [6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain. [2] Capromorelin was developed by Pfizer. [7] [8] Capromorelin was approved for veterinary use in the United States in ...
bedinvetmab - nerve growth factor inhibitor monoclonal antibody used for osteoarthritis in dogs; benazepril – ACE-inhibitor used in heart failure, hypertension, chronic kidney failure and protein-losing nephropathy; bethanechol – stimulates bladder contractions, tranquilizer, makes the patient feel no pain; bexagliflozin - oral antidiabetic ...
Ghrelin was discovered after the ghrelin receptor (called growth hormone secretagogue type 1A receptor or GHS-R) was determined in 1999. [6] The hormone name is based on its role as a g rowth h ormone- rel easing peptide , with reference to the Proto-Indo-European root gʰre- , meaning "to grow".
This gene encodes a protein that is a transmembrane receptor for growth hormone. [10] [11] Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface [12]) and the activation of an intra- and intercellular signal transduction pathway leading to growth. [13]
Growth hormone secreting pituitary tumours in dogs have only been observed in male dogs of large breeds. Excessive growth hormone secretion caused by progestone use has been seen in a variety of breeds of varying size, as well as in mixed breed dogs , the same is true of growth hormone excess brought on by the oestrous cycle.
Histrelin acetate, sold under the brand name Supprelin among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency. [2] When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes.
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.
GnRH antagonists competitively and reversibly bind to GnRH receptors in the pituitary gland, blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary.